Target identification for a promising anti-lupus drug.
Target identification is one of the more difficult aspects of modern chemical genetics. In this issue of Chemistry & Biology, Johnson et al. provide a compelling case for going through the trouble. As a byproduct of their identification of the cellular target of an anti-lupus compound, they have uncovered a powerful tool for the characterization of a fascinating molecular machine, the F1F0-ATP synthase.
Gestwicki
Jason E
JE
Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
D000251:Adenosine Triphosphatases / Q000037:antagonists & inhibitors; D000818:Animals; D001569:Benzodiazepines / Q000378:metabolism / Q000494:pharmacology; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D004791:Enzyme Inhibitors / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D007155:Immunologic Factors / Q000378:metabolism / Q000494:pharmacology; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000235:genetics*; D025261:Mitochondrial Proton-Translocating ATPases / Q000235:genetics* / Q000378:metabolism*; D019151:Peptide Library
D004791:Enzyme Inhibitors; D007155:Immunologic Factors; D019151:Peptide Library; D001569:Benzodiazepines; D000251:Adenosine Triphosphatases; C474451:F1F0-ATP synthase; D025261:Mitochondrial Proton-Translocating ATPases; C468549:Bz-423